Rhythm racks up $41 mln
Boston-based Rhythm, a biopharmaceutical company that focuses on treating life-threatening metabolic disorders, has closed $41 million in financing. The investors included Deerfield Management, Ipsen, OrbiMed, MPM Capital, New Enterprise Associates, Pfizer Venture Investments and Third Rock Ventures.
16 February 2017•1 min read
